About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Tet2tm1.1Iaai
targeted mutation 1.1, Iannis Aifantis
MGI:5141120
Summary 10 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
 		Tet1tm1.2Jae/Tet1tm1.2Jae
Tet2tm1.1Iaai/Tet2tm1.1Iaai
Tet3tm1.1Yzhg/Tet3tm1.1Yzhg
Tg(Rorc-cre)1Litt/0 		involves: 129 * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB MGI:7439998
cn2
 		Tet1tm1.2Jae/Tet1tm1.2Jae
Tet2tm1.1Iaai/Tet2+
Tet3tm1.1Yzhg/Tet3tm1.1Yzhg
Tg(Rorc-cre)1Litt/0 		involves: 129 * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB MGI:7439999
cn3
 		Sf3b1tm1.1Mdf/Sf3b1+
Tet2tm1.1Iaai/Tet2tm1.1Iaai
Tg(Mx1-cre)1Cgn/? 		involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA/J MGI:5823559
cn4
 		Ncstntm1.1Akli/Ncstntm1.1Akli
Tet2tm1.1Iaai/Tet2tm1.1Iaai
Tg(VAV1-cre)1Graf/0 		involves: 129S/SvEv * C57BL/6 MGI:5496428
cn5
 		Asxl1tm1.1Iaai/Asxl1tm1.1Iaai
Tet2tm1.1Iaai/Tet2tm1.1Iaai
Tg(VAV1-cre)1Graf/0 		involves: 129S/SvEv * C57BL/6 MGI:5575663
cn6
 		Tet2tm1.1Iaai/Tet2tm1.1Iaai
Tg(VAV1-cre)1Graf/0 		involves: 129S/SvEv * C57BL/6 MGI:5141146
cn7
 		Tet2tm1.1Iaai/Tet2+
Tg(VAV1-cre)1Graf/0 		involves: 129S/SvEv * C57BL/6 MGI:5141145
cn8
 		Asxl1tm1.1Iaai/Asxl1tm1.1Iaai
Tet2tm1.1Iaai/Tet2tm1.1Iaai
Tg(Mx1-cre)1Cgn/0 		involves: 129S/SvEv * C57BL/6 * CBA MGI:5575664
cn9
 		Tet2tm1.1Iaai/Tet2tm1.1Iaai
Tg(Mx1-cre)1Cgn/0 		involves: 129S/SvEv * C57BL/6 * CBA MGI:5141144
cn10
 		Tet2tm1.1Iaai/Tet2tm1.1Iaai
Tg(EIIa-cre)C5379Lmgd/0 		involves: 129S/SvEv * C57BL/6 * FVB/N MGI:5141143


Genotype
MGI:7439998
cn1
Allelic
Composition		 Tet1tm1.2Jae/Tet1tm1.2Jae
Tet2tm1.1Iaai/Tet2tm1.1Iaai
Tet3tm1.1Yzhg/Tet3tm1.1Yzhg
Tg(Rorc-cre)1Litt/0
Genetic
Background		 involves: 129 * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tet1tm1.2Jae mutation (0 available); any Tet1 mutation (143 available)
Tet2tm1.1Iaai mutation (2 available); any Tet2 mutation (779 available)
Tet3tm1.1Yzhg mutation (0 available); any Tet3 mutation (60 available)
Tg(Rorc-cre)1Litt mutation (1 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
growth/size/body
enlarged spleen ( J:333574 )
• splenomegaly at age 5 weeks

hematopoietic system
enlarged spleen ( J:333574 )
• splenomegaly at age 5 weeks

immune system
enlarged spleen ( J:333574 )
• splenomegaly at age 5 weeks
enlarged lymph nodes ( J:333574 )
• lymphadenopathy at age 5 weeks




Genotype
MGI:7439999
cn2
Allelic
Composition		 Tet1tm1.2Jae/Tet1tm1.2Jae
Tet2tm1.1Iaai/Tet2+
Tet3tm1.1Yzhg/Tet3tm1.1Yzhg
Tg(Rorc-cre)1Litt/0
Genetic
Background		 involves: 129 * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tet1tm1.2Jae mutation (0 available); any Tet1 mutation (143 available)
Tet2tm1.1Iaai mutation (2 available); any Tet2 mutation (779 available)
Tet3tm1.1Yzhg mutation (0 available); any Tet3 mutation (60 available)
Tg(Rorc-cre)1Litt mutation (1 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
hematopoietic system
decreased effector memory T-helper cell number ( J:333574 )
• greatly reduced CD4 expression upon T cell proliferation

immune system
immune system phenotype ( J:333574 )
N
• no autoimmune phenotypes
• normal spleen and lymph node size
• normal proportions of naive CD44- CD62L+ T lymphocyte compartments
decreased effector memory T-helper cell number ( J:333574 )
• greatly reduced CD4 expression upon T cell proliferation




Genotype
MGI:5823559
cn3
Allelic
Composition		 Sf3b1tm1.1Mdf/Sf3b1+
Tet2tm1.1Iaai/Tet2tm1.1Iaai
Tg(Mx1-cre)1Cgn/?
Genetic
Background		 involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA/J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Sf3b1tm1.1Mdf mutation (2 available); any Sf3b1 mutation (74 available)
Tet2tm1.1Iaai mutation (2 available); any Tet2 mutation (779 available)
Tg(Mx1-cre)1Cgn mutation (7 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
hematopoietic system
enlarged spleen ( J:234976 )
• post-piPC treatment
abnormal erythropoiesis ( J:234976 )
• block in erythroblast development results in an increase in cells at development stage R2 and a decrease in R4 population in spleen by 12 weeks post-piPC
abnormal myelopoiesis ( J:234976 )
• transplantation of bone marrow from mutants into lethally irradiated CD45.1 recipient mice that were treated with pIPC results in increasing (46.5% to 90%) donor chimerism beginning at 16 weeks post transplantation as compared to mice carrying only the Sf3b1tm1.1Mdf allele and wild-type
hypochromic macrocytic anemia ( J:234976 )
• progressive macrocytic anemia 45 weeks post pIPC treatment
abnormal megakaryocyte morphology ( J:234976 )
• spleens contain dysplastic megakaryocytes 45 weeks post-piPC treatment
abnormal erythroid progenitor cell morphology ( J:234976 )
• spleens contain dysplastic erythroid progenitors 45 weeks post-piPC treatment
increased mean corpuscular volume ( J:234976 )
• observed at 45 weeks post-pIPC injection
• phenotype is increased in severity as compared to mice carrying only the Sf3b1tm1.1Mdf allele
macrocytosis ( J:234976 )
• post-pIPC treatment
increased granulocyte number ( J:234976 )
• increased percentage of granulocytes in peripheral blood and bone marrow at 45 weeks post-pIPC
decreased B cell number ( J:234976 )
• decrease in percentage of B cells in the spleen and bone marrow 45 weeks post-pIPC
increased hematopoietic stem cell number ( J:234976 )
• increase in long term repopulating hematopoietic stem cells (LT-HSC) at 12 and 45 weeks as compared to wild-type
• increase in multi-potent progenitors (MPP) in bone marrow 12 weeks post-piPC treatment

immune system
enlarged spleen ( J:234976 )
• post-piPC treatment
abnormal myelopoiesis ( J:234976 )
• transplantation of bone marrow from mutants into lethally irradiated CD45.1 recipient mice that were treated with pIPC results in increasing (46.5% to 90%) donor chimerism beginning at 16 weeks post transplantation as compared to mice carrying only the Sf3b1tm1.1Mdf allele and wild-type
increased granulocyte number ( J:234976 )
• increased percentage of granulocytes in peripheral blood and bone marrow at 45 weeks post-pIPC
decreased B cell number ( J:234976 )
• decrease in percentage of B cells in the spleen and bone marrow 45 weeks post-pIPC

growth/size/body
enlarged spleen ( J:234976 )
• post-piPC treatment

Mouse Models of Human Disease
 DO ID OMIM ID(s) Ref(s)
myelodysplastic syndrome DOID:0050908 OMIM:614286
 J:234976




Genotype
MGI:5496428
cn4
Allelic
Composition		 Ncstntm1.1Akli/Ncstntm1.1Akli
Tet2tm1.1Iaai/Tet2tm1.1Iaai
Tg(VAV1-cre)1Graf/0
Genetic
Background		 involves: 129S/SvEv * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ncstntm1.1Akli mutation (0 available); any Ncstn mutation (34 available)
Tet2tm1.1Iaai mutation (2 available); any Tet2 mutation (779 available)
Tg(VAV1-cre)1Graf mutation (1 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:196407 )
• mice die at 26 weeks

immune system
enlarged spleen ( J:196407 )
• with massive infiltration of differentiated and blast-like myeloid cells
myeloid hyperplasia ( J:196407 )
• increased circulating blast-like cells at 7 weeks after birth
• massive infiltration of differentiated and blast-like myeloid cells in the spleen
increased leukocyte cell number ( J:196407 )
• with an increase in absolute myelomonocytic and blast-like cells 7 weeks after birth

neoplasm
abnormal tumor pathology ( J:196407 )
• spleen tumor cells transplanted into lethally irradiated recipients induce increased myeloid cell counts in peripheral blood and lethality compared with cells from control mice
increased leukemia incidence ( J:196407 )
• massive infiltration of differentiated and blast-like myeloid cells in the spleen

hematopoietic system
enlarged spleen ( J:196407 )
• with massive infiltration of differentiated and blast-like myeloid cells
abnormal common myeloid progenitor cell morphology ( J:196407 )
• enlarged granulocyte-macrophage progenitor (GMP) compartment
myeloid hyperplasia ( J:196407 )
• increased circulating blast-like cells at 7 weeks after birth
• massive infiltration of differentiated and blast-like myeloid cells in the spleen
increased leukocyte cell number ( J:196407 )
• with an increase in absolute myelomonocytic and blast-like cells 7 weeks after birth

growth/size/body
enlarged spleen ( J:196407 )
• with massive infiltration of differentiated and blast-like myeloid cells




Genotype
MGI:5575663
cn5
Allelic
Composition		 Asxl1tm1.1Iaai/Asxl1tm1.1Iaai
Tet2tm1.1Iaai/Tet2tm1.1Iaai
Tg(VAV1-cre)1Graf/0
Genetic
Background		 involves: 129S/SvEv * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Asxl1tm1.1Iaai mutation (1 available); any Asxl1 mutation (116 available)
Tet2tm1.1Iaai mutation (2 available); any Tet2 mutation (779 available)
Tg(VAV1-cre)1Graf mutation (1 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
hematopoietic system
hematopoietic system phenotype ( J:208092 )
N
• colony assays of whole bone marrow cells show restored serial-replating capacity of cells and competitive transplantation experiments show restoration of the self-renewal defect seen in single conditional Asxl1 mutants




Genotype
MGI:5141146
cn6
Allelic
Composition		 Tet2tm1.1Iaai/Tet2tm1.1Iaai
Tg(VAV1-cre)1Graf/0
Genetic
Background		 involves: 129S/SvEv * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tet2tm1.1Iaai mutation (2 available); any Tet2 mutation (779 available)
Tg(VAV1-cre)1Graf mutation (1 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
hematopoietic system
enlarged spleen ( J:174053 )
• at 20 weeks
increased spleen weight ( J:174053 )
• at 20 weeks
abnormal common myeloid progenitor cell morphology ( J:174053 )
• increased myeloid progenitors in the spleen
myeloid hyperplasia ( J:174053 )
• mice exhibit an increase in the GMP population (including monocyte and granulocyte progenitors) compared with wild-type mice
increased leukocyte cell number ( J:174053 )
• at 20 weeks, progressive in the peripheral blood
abnormal myeloid leukocyte morphology ( J:174053 )
• at 20 weeks, bone marrow and peripheral lymphoid tissue exhibit myeloid dysplasia (including blasts, promyelocytes, myelocytes, or metamyelocytes) unlike in wild-type mice
abnormal hematopoietic stem cell physiology ( J:174053 )
• hematopoietic progenitors exhibit increased serial replating capacity compared with control cells

neoplasm
increased chronic myelocytic leukemia incidence ( J:174053 )
• at 20 weeks, mice exhibit chronic myelomonocytic leukemia (CMML)-like phenotype unlike wild-type mice

immune system
enlarged spleen ( J:174053 )
• at 20 weeks
increased spleen weight ( J:174053 )
• at 20 weeks
myeloid hyperplasia ( J:174053 )
• mice exhibit an increase in the GMP population (including monocyte and granulocyte progenitors) compared with wild-type mice
increased leukocyte cell number ( J:174053 )
• at 20 weeks, progressive in the peripheral blood
abnormal myeloid leukocyte morphology ( J:174053 )
• at 20 weeks, bone marrow and peripheral lymphoid tissue exhibit myeloid dysplasia (including blasts, promyelocytes, myelocytes, or metamyelocytes) unlike in wild-type mice

growth/size/body
enlarged spleen ( J:174053 )
• at 20 weeks
increased spleen weight ( J:174053 )
• at 20 weeks




Genotype
MGI:5141145
cn7
Allelic
Composition		 Tet2tm1.1Iaai/Tet2+
Tg(VAV1-cre)1Graf/0
Genetic
Background		 involves: 129S/SvEv * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tet2tm1.1Iaai mutation (2 available); any Tet2 mutation (779 available)
Tg(VAV1-cre)1Graf mutation (1 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
hematopoietic system
increased leukocyte cell number ( J:174053 )
• progressive in the peripheral blood
increased monocyte cell number ( J:174053 )
• in the peripheral blood
abnormal hematopoietic stem cell physiology ( J:174053 )
• hematopoietic progenitors exhibit increased serial replating capacity compared with control cells

immune system
increased leukocyte cell number ( J:174053 )
• progressive in the peripheral blood
increased monocyte cell number ( J:174053 )
• in the peripheral blood




Genotype
MGI:5575664
cn8
Allelic
Composition		 Asxl1tm1.1Iaai/Asxl1tm1.1Iaai
Tet2tm1.1Iaai/Tet2tm1.1Iaai
Tg(Mx1-cre)1Cgn/0
Genetic
Background		 involves: 129S/SvEv * C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Asxl1tm1.1Iaai mutation (1 available); any Asxl1 mutation (116 available)
Tet2tm1.1Iaai mutation (2 available); any Tet2 mutation (779 available)
Tg(Mx1-cre)1Cgn mutation (7 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:208092 )
• 40% of mice treated with polyinosinicpolycytidylic acid (pI:pC) at 4 weeks of life die by 50 weeks of age

hematopoietic system
abnormal myelopoiesis ( J:208092 )
• transplantation of bone marrow from mutants into lethally irradiated CD45.1 recipient mice that were treated with pI:pC results in a myelodysplastic syndrome and mice exhibit lower white blood cell counts and hematocrit, presence of dysplastic erythroid precursors, dysplastic myloid cells, and increased extramedullary hematopoiesis

immune system
abnormal myelopoiesis ( J:208092 )
• transplantation of bone marrow from mutants into lethally irradiated CD45.1 recipient mice that were treated with pI:pC results in a myelodysplastic syndrome and mice exhibit lower white blood cell counts and hematocrit, presence of dysplastic erythroid precursors, dysplastic myloid cells, and increased extramedullary hematopoiesis




Genotype
MGI:5141144
cn9
Allelic
Composition		 Tet2tm1.1Iaai/Tet2tm1.1Iaai
Tg(Mx1-cre)1Cgn/0
Genetic
Background		 involves: 129S/SvEv * C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tet2tm1.1Iaai mutation (2 available); any Tet2 mutation (779 available)
Tg(Mx1-cre)1Cgn mutation (7 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
hematopoietic system
enlarged spleen ( J:234976 )
• post-pIPC treatment
abnormal erythropoiesis ( J:234976 )
• block in erythroblast development resulting in an increase at development stage R2 and a decrease in R4 population in spleen at 45 weeks post-piPC
abnormal myelopoiesis ( J:234976 )
• transplantation of bone marrow from mutants into lethally irradiated CD45.1 recipient mice that were treated with post-pIPC results in 100% donor chimerism by 24 weeks as compared to approximately 25% in wild-type
increased granulocyte number ( J:234976 )
• increased percentage of granulocytes in peripheral blood and bone marrow at 45 weeks post-pIPC
decreased B cell number ( J:234976 )
• decrease in percentage of B cells in the spleen and bone marrow 45 weeks post-pIPC
increased hematopoietic stem cell number ( J:234976 )
• increase in long term repopulating hematopoietic stem cells (LT-HSC) in bone marrow 45 weeks post-piPC treatment
• increase in multi-potent progenitors (MPP) in bone marrow 12 weeks post-piPC treatment
• increase in short term repopulating hematopoietic stem cells (ST-HSC) in bone marrow 45 weeks post-piPC treatment
abnormal hematopoietic stem cell physiology ( J:174053 )
• in transplantation experiments, pIpC-treated hematopoietic stem cells exhibit increased self-renewal compared with control cells

immune system
enlarged spleen ( J:234976 )
• post-pIPC treatment
abnormal myelopoiesis ( J:234976 )
• transplantation of bone marrow from mutants into lethally irradiated CD45.1 recipient mice that were treated with post-pIPC results in 100% donor chimerism by 24 weeks as compared to approximately 25% in wild-type
increased granulocyte number ( J:234976 )
• increased percentage of granulocytes in peripheral blood and bone marrow at 45 weeks post-pIPC
decreased B cell number ( J:234976 )
• decrease in percentage of B cells in the spleen and bone marrow 45 weeks post-pIPC

mortality/aging
premature death ( J:208092 )
• 17.7% of mice treated with polyinosinicpolycytidylic acid (pIpC) at 4 weeks of life die by 50 weeks of age

growth/size/body
enlarged spleen ( J:234976 )
• post-pIPC treatment




Genotype
MGI:5141143
cn10
Allelic
Composition		 Tet2tm1.1Iaai/Tet2tm1.1Iaai
Tg(EIIa-cre)C5379Lmgd/0
Genetic
Background		 involves: 129S/SvEv * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tet2tm1.1Iaai mutation (2 available); any Tet2 mutation (779 available)
Tg(EIIa-cre)C5379Lmgd mutation (4 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
normal phenotype
no abnormal phenotype detected ( J:174053 )
• mice are born with at the expected Mendelian ratio with normal growth and organ development




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
11/12/2024
MGI 6.24 		The Jackson Laboratory